1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting
(
- Contribution to journal › Article
- 2024
-
Mark
Belimumab concentration measurements using a homologous anti-idiotype immunoassay
(
- Contribution to journal › Article
- 2021
-
Mark
De novo lupus nephritis during treatment with belimumab
(
- Contribution to journal › Article
- 2019
-
Mark
Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
(
- Contribution to journal › Article
- 2018
-
Mark
Smoking reduces the efficacy of belimumab in mucocutaneous lupus
(
- Contribution to journal › Article
- 2017
-
Mark
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
(
- Contribution to journal › Article